BH3-mimetics: recent developments in cancer therapy

Table 10 Selected phase I clinical trials conducted with Navitoclax as a single or combined therapeutic in untreated and pre-treated patients with Docetaxel (DOC), Erlotinib (ERLO), Gemcitabine (GEM), Carboplatin (CARB), Paclitaxel (PAC), Etopiside (ETOP), Cisplatin (CISP) against Advanced Solid Tumors (AST), non-small cell lung cancer (NSCLC), Prostate Cancer (PC), Squamous cell carcinoma (SCC) and lymphoid malignancies (LM) for Maximum Tolerated Doses (MTD) outcomes

Navitoclax	Combined	Patients	Disease	Outcomes	ORR	Stabilized	Ref
NCT00888108	DOC	39/41 Pre-Treated	AST	MTD	4/35 PR	–	[392]
NCT01009073	ERLO	–	NSCLC, PC, SCC	MTD	0% ORR	27%	[393]
NCT00887757	GEM	Pre-Treated	ST	MTD	0% ORR	54%	[394]
NCT00891605	CARB/PAC	–	ST	TERMINATED	5.3% PR	36.80%	[395]
NCT00878449	ETOP/CISP	Untreated (14 days)	SCLC	MTD	–	–	[396]
NCT00445198	-single-	Pre-Treated	NSCLC, ST	0%	1/47 PR	22.8% (13 m)	[390]
NCT00406809	-single-	–	LM	MTD	10/46 PR	–	[389, 397]

The clinical trials reference numbers highlighted in bold (left column), the evaluation of a single therapy alone is highlighted by -single-. Objective Response Rates (ORR) and Partial Responses (PR) are expressed as responding patient numbers/numbers assessed, or as percentages (%). Disease stabilization (Stabilized) effects (as percentage responders) are highlighted in months (m). The corresponding references for the studies are highlighted in the column on the right (Ref)

ISSN: 1756-9966